Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LGND Ligand Pharmaceuticals	$156.01 +2.2%	$125.17	$93.58 ▼ $157.54	$2.99B	0.85	338,513 shs	352,303 shs
MIRM Mirum Pharmaceuticals	$65.14 +0.6%	$52.06	$36.86 ▼ $67.45	$3.25B	0.94	577,855 shs	1.11 million shs
OXBDF Oxford BioMedica	$6.26 -0.6%	$4.99	$3.15 ▼ $6.60	$663.32M	1.08	475 shs	700 shs
XENE Xenon Pharmaceuticals	$37.67 +4.7%	$32.31	$26.74 ▼ $46.00	$2.78B	1.16	1.01 million shs	1.56 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LGND Ligand Pharmaceuticals	+3.86%	+12.98%	+25.46%	+45.29%	+53.30%
MIRM Mirum Pharmaceuticals	-1.75%	+24.85%	+22.90%	+45.80%	+44.66%
OXBDF Oxford BioMedica	-0.63%	-5.15%	+31.24%	+59.43%	+45.58%
XENE Xenon Pharmaceuticals	+5.51%	+4.62%	+11.74%	+21.02%	-7.36%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LGND Ligand Pharmaceuticals	3.4515 of 5 stars	1.5	1.0	0.0	4.4	2.6	2.5	1.9
MIRM Mirum Pharmaceuticals	4.0244 of 5 stars	3.6	0.0	0.0	4.2	3.2	2.5	0.6
OXBDF Oxford BioMedica	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	1.9771 of 5 stars	3.5	1.0	0.0	0.0	2.4	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LGND Ligand Pharmaceuticals	3.00	Buy	$157.00	0.63% Upside
MIRM Mirum Pharmaceuticals	3.13	Buy	$74.13	13.79% Upside
OXBDF Oxford BioMedica	0.00	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	3.00	Buy	$53.20	41.23% Upside

Current Analyst Ratings Breakdown

Latest OXBDF, MIRM, LGND, and XENE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	XENE Xenon Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00
8/12/2025	XENE Xenon Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$57.00 ➝ $55.00
8/12/2025	XENE Xenon Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$42.00 ➝ $43.00
8/11/2025	MIRM Mirum Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy	$89.00
8/8/2025	LGND Ligand Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$155.00 ➝ $185.00
8/8/2025	MIRM Mirum Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$77.00 ➝ $89.00
8/7/2025	MIRM Mirum Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy
8/7/2025	MIRM Mirum Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Market Outperform ➝ Market Outperform	$79.00 ➝ $81.00
8/7/2025	MIRM Mirum Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$77.00 ➝ $82.00
8/7/2025	MIRM Mirum Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$73.00 ➝ $80.00
7/30/2025	LGND Ligand Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$145.00 ➝ $162.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LGND Ligand Pharmaceuticals	$167.13M	18.30	$1.64 per share	95.03	$42.28 per share	3.69
MIRM Mirum Pharmaceuticals	$429.16M	7.63	N/A	N/A	$5.08 per share	12.82
OXBDF Oxford BioMedica	$111.34M	5.96	N/A	N/A	$1.01 per share	6.20
XENE Xenon Pharmaceuticals	$9.43M	308.03	N/A	N/A	$8.22 per share	4.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LGND Ligand Pharmaceuticals	-$4.03M	-$4.00	N/A	42.05	N/A	-40.44%	-9.21%	-8.09%	N/A
MIRM Mirum Pharmaceuticals	-$87.94M	-$1.21	N/A	N/A	N/A	-13.65%	-24.76%	-8.50%	N/A
OXBDF Oxford BioMedica	-$195.90M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	-$234.33M	-$3.55	N/A	N/A	N/A	N/A	-38.50%	-36.47%	N/A

Latest OXBDF, MIRM, LGND, and XENE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	XENE Xenon Pharmaceuticals	-$1.03	-$1.07	-$0.04	-$1.07	N/A	N/A
8/7/2025	Q2 2025	LGND Ligand Pharmaceuticals	$1.54	$1.60	+$0.06	$0.24	$43.87 million	$47.63 million
8/6/2025	Q2 2025	MIRM Mirum Pharmaceuticals	-$0.31	-$0.12	+$0.19	-$0.12	$107.91 million	$127.79 million
5/14/2025	Q1 2025	MIRM Mirum Pharmaceuticals	-$0.35	-$0.30	+$0.05	-$0.30	$98.47 million	$111.59 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OXBDF Oxford BioMedica	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LGND Ligand Pharmaceuticals	N/A	5.45	5.21
MIRM Mirum Pharmaceuticals	1.21	3.13	2.97
OXBDF Oxford BioMedica	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	15.14	17.66

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LGND Ligand Pharmaceuticals	91.28%
MIRM Mirum Pharmaceuticals	N/A
OXBDF Oxford BioMedica	N/A
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
LGND Ligand Pharmaceuticals	7.00%
MIRM Mirum Pharmaceuticals	14.36%
OXBDF Oxford BioMedica	N/A
XENE Xenon Pharmaceuticals	4.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LGND Ligand Pharmaceuticals	80	19.60 million	17.94 million	Optionable
MIRM Mirum Pharmaceuticals	140	50.24 million	43.02 million	Optionable
OXBDF Oxford BioMedica	891	105.96 million	N/A	Not Optionable
XENE Xenon Pharmaceuticals	210	77.11 million	73.61 million	Optionable

OXBDF, MIRM, LGND, and XENE Headlines

Recent News About These Companies

Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Up After Analyst Upgrade

August 13 at 10:52 AM | marketbeat.com

Royal Bank Of Canada Has Lowered Expectations for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price

August 13 at 10:25 AM | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Given New $43.00 Price Target at Wedbush

August 13 at 9:40 AM | marketbeat.com

Wedbush Issues Positive Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price

August 13 at 3:31 AM | americanbankingnews.com

TD Cowen Reaffirms Their Buy Rating on Xenon (XENE)

August 13 at 2:39 AM | theglobeandmail.com

Xenon Completes Patient Recruitment for Phase 3 Study

August 13 at 2:39 AM | theglobeandmail.com

Xenon Pharmaceuticals (NASDAQ:XENE) Announces Quarterly Earnings Results

August 12 at 9:25 PM | marketbeat.com

Xenon Pharmaceuticals price target lowered to $55 from $57 at RBC Capital

August 12 at 8:39 PM | msn.com

Xenon Pharmaceuticals: Pushing Azetukalner Towards Finish Line With Phase 3 2026 Data Release

August 12 at 3:05 PM | seekingalpha.com

Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus

August 12 at 11:21 AM | zacks.com

Xenon Pharmaceuticals Reports Q2 2025 Progress and Outlook

August 12 at 3:55 AM | msn.com

Xenon Pharmaceuticals Inc. (XENE) Q2 2025 Earnings Call Transcript

August 11 at 12:03 AM | seekingalpha.com

Xenon Pharmaceuticals: Q2 Earnings Snapshot

August 11 at 10:54 PM | chron.com

Xenon Pharmaceuticals jumps after massive earnings beat

August 11 at 5:54 PM | investing.com

Xenon Reports Second Quarter 2025 Financial Results & Business Update

August 11 at 4:01 PM | globenewswire.com

Mutual of America Capital Management LLC Acquires Shares of 48,763 Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

August 11 at 4:51 AM | marketbeat.com

Xenon Pharma Q2 2025 Earnings Preview

August 11 at 2:52 AM | seekingalpha.com

2XENE : A Look Ahead: Xenon Pharmaceuticals's Earnings Forecast

August 8, 2025 | benzinga.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives $54.82 Consensus PT from Brokerages

August 7, 2025 | americanbankingnews.com

Xenon Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:XENE)

August 7, 2025 | marketbeat.com

Xenon Pharmaceuticals (XENE) Expected to Announce Earnings on Monday

August 6, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OXBDF, MIRM, LGND, and XENE Company Descriptions

Ligand Pharmaceuticals NASDAQ:LGND

$156.01 +3.32 (+2.17%)

Closing price 04:00 PM Eastern

Extended Trading

$155.99 -0.02 (-0.01%)

As of 04:38 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Mirum Pharmaceuticals NASDAQ:MIRM

$65.14 +0.42 (+0.65%)

Closing price 04:00 PM Eastern

Extended Trading

$65.16 +0.02 (+0.02%)

As of 07:30 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Oxford BioMedica OTCMKTS:OXBDF

$6.26 -0.04 (-0.63%)

As of 10:55 AM Eastern

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

Xenon Pharmaceuticals NASDAQ:XENE

$37.67 +1.68 (+4.67%)

Closing price 04:00 PM Eastern

Extended Trading

$37.60 -0.08 (-0.20%)

As of 05:20 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time